Atovaquone/proguanil

Atovaquone/proguanil
Combination of
Atovaquone	Antimalarial medication
Proguanil	Antimalarial medication
Clinical data
Trade names	Malarone, Malanil, others
AHFS/Drugs.com	Monograph
License data	US DailyMed: Atovaquone_and_proguanil;
Pregnancy; category	AU: B2;
Routes of; administration	By mouth
ATC code	P01BB51 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	156879-69-5;
PubChem CID	11954242;
ChemSpider	21230364 ;
KEGG	D02472 ;
CompTox Dashboard (EPA)	DTXSID90935554 ;
	(what is this?) (verify)

Atovaquone/proguanil, sold under the brand name Malarone among others, is a fixed-dose combination medication used to treat and prevent malaria, including chloroquine-resistant malaria. It contains atovaquone and proguanil. It is not recommended for severe or complicated malaria. It is taken by mouth.

Common side effects include abdominal pain, vomiting, diarrhea, cough, and itchiness. Serious side effects may include anaphylaxis, Stevens–Johnson syndrome, hallucinations, and liver problems. Side effects are generally mild. It is unclear if use during pregnancy or breastfeeding is safe for the baby. It is not recommended to prevent malaria in those with poor kidney function. Atovaquone works by interfering with the function of mitochondria in malaria while proguanil blocks dihydrofolate reductase.

Atovaquone/proguanil was approved for medical use in the United States in 2000. It has been available as a generic medication since 2011.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.